Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy

European Journal of Ophthalmology

Volumn 20, Issue 6, 2010, Pages 1047-1052

  Hernández Da Mota, Sergio E ^a   Nuñez Solorio, Silvia M ^b  

^a General Hospital Dr Miguel Silva   (Mexico)

^b Hospital Infantil Eva Sámano de López Mateos   (Mexico)

Author keywords

Bevacizumab; Proliferative diabetic retinopathy; Tractional retinal detachment; Vitrectomy

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN A1C;

ADJUVANT THERAPY; ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPERATION DURATION; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 77954477722     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067211002000604     Document Type: Article

References (32)

1. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35. (Pubitemid 40848295)
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
3. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-72. (Pubitemid 44279358)
4. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47. (Pubitemid 40797459)
5. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-9. (Pubitemid 41073113)
6. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
7. Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol 1994; 87: 223-32. (Pubitemid 24326967)
8. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009; 23: 117-23.
9. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009; 23: 108-11.
10. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26: 699-700.
11. Satterthwaite FW. An approximate distribution of estimates of variance components. Biom Bull 1946; 2: 110-4.
12. Elliott A, Flanagan D. Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 438-41. (Pubitemid 20291024)
13. Diabetic Retinopathy Vitrectomy Study. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management: Diabetic Retinopathy Vitrectomy Study Report 1. Ophthalmology 1985; 92: 492-502.
14. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 2. Arch Ophthalmol 1985; 103: 1644-52.
15. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology 1988; 95: 1307-20.
16. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: clinical application of results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 4. Ophthalmology 1988; 95: 1321-34.
17. Diabetic Retinopathy Vitrectomy Study Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5 [erratum in 1990; 108: 1452]. Arch Ophthalmol 1990; 108: 958-64.
18. Faulborn J, Conway BP, Machemer R. Surgical complications of pars plana vitreous surgery. Ophthalmology 1978; 85: 116-25.
19. Carter JB, Michels RG, Glaser BM, et al. Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology 1990; 97: 848-53.
20. Chagnon A, Payan J, Levy C, Chassain C. Intraocular pressure during vitrectomy in the diabetic patient. Bull Soc Ophtalmol Fr 1989; 89: 171-8.
21. Thompson JT, Glaser BM, Michels RG, et al. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986; 93: 279-82. (Pubitemid 16081374)
22. O'Grady GE. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986; 93: 1367.
23. Imamura Y, Kamei M, Minami M, et al. Heparin-assisted removal of clotting preretinal hemorrhage during vitrectomy for proliferative diabetic retinopathy. Retina 2005; 25: 793-5. (Pubitemid 41254555)
24. Siam AL. External diathermy treatment of proliferative diabetic retinopathy with vitreous haemorrhage. Br J Ophthalmol 1986; 70: 118-21.
25. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007; 144: 124-6. (Pubitemid 46963178)
26. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005. (Pubitemid 44973218)
27. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29: 768-74.
28. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23: 240-2. (Pubitemid 46986604)
29. Arevalo JF, Maia M, Flynn H Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-6. (Pubitemid 351224097)
30. Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol 2007; 21: 185-7.
31. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Bio Drugs 2007; 21: 245-57. (Pubitemid 47104980)
32. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116: 927-38.